publication date: Oct. 18, 2019
Issue 39 - Oct. 18, 2019
  • E-cigarette smoke associated with lung cancer, inflammation, as federal agencies respond to vaping deaths

    E-cigarette smoke, like tobacco smoke, may, in fact, cause cancer, new studies suggest.

    According to one just-reported study, mice exposed to e-cigarette smoke were five times more likely to develop lung cancer, and 10 times more likely to develop precancerous lesions of the bladder.

  • Guest Editorial

    Museum malignancy:

    What the Sacklers and Philip Morris have in common

    Since March 2018, P.A.I.N. (Prescription Addiction Intervention Now), an organization founded in 2017 by photographer Nan Goldin, has held demonstrations at art museums in New York, Washington, DC, Boston, London and Paris to protest their acceptance of money from the Sackler family, owners of Purdue Pharma, a company that been accused of fomenting the prescription opioid addiction crisis.

  • In Brief

    • Brown named Syapse chief medical officer
    • Barker, Fingert, Hayes-Jordan and Vadaparampil named to NCAB
    • Virginia Tech announces cancer research initiative
    • Ribas, Jaffee, Eshhar, Samelson, Seed and Weiss share Coley awards for immunology
    • Cambridge’s Nik-Zainal wins Josef Steiner Cancer Research prize
    • Backman named associate director for research technology at Northwestern
    • City of Hope provides cancer support services to Amazon employees 
    • NCI grant UNC to help patients navigate costs of cancer care
    • Third Edition of Cancer Atlas highlights patterns and inequities in cancer burden
  • TCCL Logo

  • Real World Evidence

    Real-world data, evidence should be leveraged in clinical research to better include and ultimately treat larger patient populations

    The growth of personalized medicine in oncology continues to fuel a shift from traditional chemotherapies to immunotherapy. Currently, there are more than 30 immunotherapies approved for use in the United States, with more than 2,300 immunotherapy clinical trials listed on ClinicalTrials.gov.

  • Clinical Roundup

    • UCLA opens CAR T-cell trial focused on the most common types of lymphoma, leukemia
    • Results from STELLAR trial in MPM published in The Lancet Oncology
    • IASLC invites comments on “Multidisciplinary Recommendations for Pathologic Assessment of Lung Cancer Resection Specimens Following Neoadjuvant Therapy”
    • Expert second opinion improves reliability of melanoma diagnoses
  • Drugs & Targets

    • Xenikos receives Fast Track designation for T-Guard for steroid-refractory SR-aGVHD
    • Flatiron announces clinical decision support application through Epic’s App Orchard

Copyright (c) 2019 The Cancer Letter Inc.